Journal of Peking University(Health Sciences) ›› 2019, Vol. 51 ›› Issue (3): 402-408. doi: 10.19723/j.issn.1671-167X.2019.03.005

Previous Articles     Next Articles

Expression and clinical significance of chemokine CXCL10 and its receptor CXCR3 in hepatocellular carcinoma

Jing ZHANG,Jie CHEN,Gui-wen GUAN,Ting ZHANG,Feng-min LU(),Xiang-mei CHEN()   

  1. Department of Microbiology & Infectious Disease Center, Peking University School of Basic Medical Sciences, Beijing 100191, China
  • Received:2019-03-25 Online:2019-05-10 Published:2019-06-26
  • Supported by:
    Supported by Beijing Natural Science Foundation(7182079)

Abstract: Objective: To explore the expression and clinical significance of chemokine CXCL10 and CXCR3 in hepatocellular carcinoma (HCC).Methods: The expression and prognostic of CXCL10 and CXCR3 in HCC tumor tissues and non-tumor tissues were analyzed in two different publicly available databases the Cancer Genome Atlas (TCGA) and Liver Cancer Institute (LCI). In addition, quantitative real-time PCR (qPCR) was used to detect the mRNA expression of CXCL10 and CXCR3 in 45 HCC cli-nical samples with HBV infection background. Pearson correlation and Spearman rank correlation were used to determine the correlation between the expression level of CXCL10 and CXCR3 in tumor and non-tumor tissues. Results: In TCGA database, the expression of CXCL10 in HCC tumor tissues was significantly higher than that in non-tumor tissues (nonpaired samples: 3.379±2.081 vs. 2.213±2.274, P<0.001; paired samples: 3.159±2.267 vs. 2.213±2.274, P=0.018). Similarly in LCI datebase (7.625±1.683 vs. 7.287±1.328, P=0.009). And higher CXCL10 expression was significantly associated with a better prognosis in the patients with HCC both in TCGA and LCI database (P=0.107, P=0.002). In TCGA database, the expression of CXCR3 in HCC tumor tissues was significantly higher than that in non-tumor tissues (nonpaired samples: -0.906±1.697 vs. -1.978±1.629, P<0.001; paired samples: -1.329±1.732 vs. -1.978±1.629, P=0.037), while lower in LCI database (3.989±0.339 vs. 4.074±0.309, P=0.003). In both databases, higher CXCR3 expression was significantly associated with a better prognosis in the HCC patients (P=0.004, P=0.014). Furthermore, in TCGA database, the expression level of CXCL10 and CXCR3 was positively correlated both in HCC tumor tissues and matched non-tumor tissues (r=0.584, P<0.001; r=0.776, P<0.001). The qPCR assay showed that the expression of CXCL10 in HBV-related HCC tumor tissues was significantly higher than those in normal liver tissues [0.479(0.223, 1.094) vs. 0.131(0.106, 0.159), P=0.010], and the expression in HBV-related non-tumor tissues was also significantly higher than those in normal liver tissues [0.484(0.241, 0.846) vs. 0.131(0.106, 0.159), P<0.001]. The same was true as CXCR3 [0.011(0.006, 0.019) vs. 0.002(0.001, 0.004), P=0.004; 0.016(0.011, 0.021) vs. 0.002(0.001, 0.004), P<0.001]. However there was no significant difference of CXCL10 and CXCR3 between tumor tissues and matched non-tumor tissues (P=1.000, P=0.374).Conclusion: Expression of CXCL10 was up-regulated in HCC tissues, expression of CXCR3 was down-regulated in HBV-related HCC tissues, and the higher expression of both genes was correlated with better overall survival in HCC patients.

Key words: Chemokine, Chemokine receptor, Hepatocellular carcinoma

CLC Number: 

  • R393

Figure 1

Expression and prognostic of CXCL10 and CXCR3 in HCC tumor tissues and non-tumor tissues in TCGA database A, the expression of CXCL10 in nonpaired HCC tumor tissues (n=370) and non-tumor tissues (n=50); B, the expression of CXCL10 in paired HCC tumor tissues and non-tumor tissues (n=50); C, the prognostic of CXCL10 in HCC patients; D, the expression of CXCR3 in nonpaired HCC tumor tissues (n=370) and non-tumor tissues (n=50); E, the expression of CXCR3 in paired HCC tumor tissues and non-tumor tissues (n=50); F, the prognostic of CXCR3 in HCC patients. Results were showed as x?±s."

Figure 2

The expression and prognostic of CXCL10 and CXCR3 in HCC tumor tissues and non-tumor tissues in LCI database A, the expression of CXCL10 in HCC tumor tissues and non-tumor tissues (n=204); B, the prognostic of CXCL10 in HCC patients (n=204); C, the expression of CXCR3 in HCC tumor tissues and non-tumor tissues (n=204); D, the prognostic of CXCR3 in HCC patients (n=204). Results were showed as x?±s."

Figure 3

mRNA expression of CXCL10 and CXCR3 of 45 HCC clinical samples with HBV infection background detected by qPCR A, mRNA expression of CXCL10 in HCC (n=45), non-tumor (n=45) and nomal (n=8) tissues; B, mRNA expression of CXCR3 in HCC (n=45), non-tumor (n=45) and normal (n=8) tissues. Results were showed as M (P25,P75)."

Figure 4

Correlation between the expression level of CXCL10 and CXCR3 in tumor and non-tumor tissues A, correlation between the expression level of CXCL10 and CXCR3 in tumor tissues in TCGA datebase, LCI database and clinical samples; B, correlation between the expression level of CXCL10 and CXCR3 in non-tumor tissues in TCGA datebase, LCI database and clinical samples."

[1] Joliat GR, Allemann P, Labgaa I , et al. Treatment and outcomes of recurrent hepatocellular carcinomas[J]. Langenbecks Arch Surg, 2017,402(5):737-744.
doi: 10.1007/s00423-017-1582-9
[2] El-Serag HB, Rudolph KL . Hepatocellular carcinoma: epidemio-logy and molecular carcinogenesis[J]. Gastroenterology, 2007,132(7):2557-2576.
doi: 10.1053/j.gastro.2007.04.061
[3] Hong TP, Gow P, Fink M , et al. Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed[J]. Hepatology, 2016,63(4):1205-1212.
doi: 10.1002/hep.28267
[4] Elia G, Fallahi P . Hepatocellular carcinoma and CXCR3 chemokines: a narrative review[J]. Clin Ter, 2017,168(1):e37-e41.
[5] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版)[J]. 临床肝胆病杂志, 2011,27(11):1141-1159.
[6] Kamil F, Rowe JH . How does the tumor microenvironment play a role in hepatobiliary tumors?[J]. J Gastrointest Oncol, 2018,9(1):180-195.
doi: 10.21037/jgo
[7] Tokunaga R, Zhang W, Naseem M , et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation:a target for novel cancer therapy[J]. Cancer Treat Rev, 2018,63:40-47.
doi: 10.1016/j.ctrv.2017.11.007
[8] Ren T, Zhu L, Cheng M . CXCL10 accelerates EMT and metastasis by MMP-2 in hepatocellular carcinoma[J]. Am J Transl Res, 2017,9(6):2824-2837.
[9] Hirano S, Iwashita Y, Sasaki A , et al. Increased mRNA expression of chemokines in hepatocellular carcinoma with tumor-infiltrating lymphocytes[J]. J Gastroenterol Hepatol, 2007,22(5):690-696.
[10] Chew V, Chen J, Lee D , et al. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma[J]. Gut, 2012,61(3):427-438.
doi: 10.1136/gutjnl-2011-300509
[11] Ding Q, Xia Y, Ding S , et al. An alternatively spliced variant of CXCR3 mediates the metastasis of CD133 + liver cancer cells induced by CXCL9 [J]. Oncotarget, 2016,7(12):14405-14414.
[12] 任颖, 阚云珍, 孔令非 . 靶向沉默CXCR3对肝癌细胞恶性增殖的作用研究[J]. 中华肝脏病杂志, 2018,26(7):508-512.
[13] Billottet C, Quemener C, Bikfalvi A . CXCR3, a double-edged sword in tumor progression and angiogenesis[J]. Biochim Biophys Acta, 2013,1836(2):287-295.
[1] Hua ZHONG,Li-ling XU,Ming-xin BAI,Yin SU. Effect of chemokines CXCL9 and CXCL10 on bone erosion in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1026-1031.
[2] PANG Yong,ZHANG Sha,YANG Hua,ZHOU Rou-li. Serum LAPTM4B-35 protein as a novel diagnostic marker for hepatocellular carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 710-715.
[3] Bo MA,Zhi-hua TIAN,Li QU,Yue-xiang LIU,Hong ZHANG,Hui-rong DING. Establishment and gene expression analysis of drug-resistant cell lines in hepatocellular carcinoma induced by sorafenib [J]. Journal of Peking University (Health Sciences), 2020, 52(2): 207-213.
[4] Xin-yun YAO,Xiao-min GAO,Xiao-ying ZOU,Lin YUE. Role of endocytosis in cell surface CXC chemokine receptor 4 expression of stem cells from apical papilla [J]. Journal of Peking University(Health Sciences), 2019, 51(5): 893-899.
[5] Yun-bo XIE,Ji-yuan ZHANG,Mei-ling DU,Fan-ping MENG,Jun-liang FU,Li-min LIU,Song-shan WANG,Rui QU,Fang LIAN,Fei QIAO,Yang-liu CHEN,Ying-ying GAO,Ruo-nan XU,Ming SHI,Fu-sheng WANG. Efficacy and peripheral immunity analysis of allogeneic natural killer cells therapy in patients with hepatocellular carcinoma [J]. Journal of Peking University(Health Sciences), 2019, 51(3): 591-595.
[6] LIU Hong-jiang, SHI Lian-jie, HU Fan-lei, YAO Hai-hong, LI Zhan-guo, JIAYuan. Increased serum C-C chemokine ligand 19 levels correlated with B cell abnormalities in systemic lupus erythematosus [J]. Journal of Peking University(Health Sciences), 2017, 49(5): 829-834.
[7] SHI Lian-jie, LI Jian-hong, HU Fan-lei, LI Min, ZHANG Jie, LI Jiang-tao, LI Zhan-guo. Clinical significance of serum C-C chemokine ligand 19 levels in patients with rheumatoid arthritis [J]. Journal of Peking University(Health Sciences), 2016, 48(4): 667-671.
[8] ZHANG Xiao-wei, DUN Yao-jun, TANG Xu, YIN Hua-qi, HU Zhi-ping, ZHAO Yong-ping, XU Tao, LI Qing. Expression of chemokine like factor-like myelin and lymphocyte and related proteins for vesicle trafficking and membrane link transmembrane domaincontaining protein 2 in rats with varicocele [J]. Journal of Peking University(Health Sciences), 2016, 48(4): 579-583.
[9] WEN Quan, ZHAO Yu-ming, WANG Yuan-yuan, WANG Xu, LING Long, GE Li-hong. Effects of stromal cell-derived factor-1 on proliferation, migration, and odontoblastic differentiation of human dental pulp stem cells [J]. Journal of Peking University(Health Sciences), 2016, 48(1): 23-29.
[10] 欧Meng-恩 , ZHANG Xiao, LIU Yun-Song, GE Yan-Jun, ZHOU Yong-Sheng. Ectopic osteogenesis of stromal cell-derived factor 1 combined with simvastatin loaded collagen scaffold in vivo [J]. Journal of Peking University(Health Sciences), 2015, 47(1): 47-51.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 188 -191 .
[2] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 319 -322 .
[3] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 333 -336 .
[4] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 337 -340 .
[5] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 346 -350 .
[6] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 351 -354 .
[7] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 369 -373 .
[8] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 377 -380 .
[9] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 420 -422 .
[10] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 443 -444 .